Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int‐1‐risk MDS patients: Results of the phase II KALLISTO trial
Erythropoiesis‐stimulating agents (ESAs) remain first‐choice to treat symptomatic anemia and delay transfusion dependence in most patients with lower‐risk myelodysplastic syndromes (MDS) without del(5q). Deferasirox increased erythroid responses in some lower‐risk MDS patients in clinical trials, and adding low‐dose deferasirox to ESA treatment may further improve erythroid response.
No Supplementary Data
No Article Media